Male lower urinary tract symptoms: Treatment with α-blockers, 5-α-reductase inhibitors, antimuscarinics, or a combination

Current Urology Reports

Volumn 8, Issue 5, 2007, Pages 370-372

  Appell, Rodney A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TOLTERODINE; VARDENAFIL;

DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; HUMAN; INCIDENCE; LOWER URINARY TRACT SYMPTOM; SHORT SURVEY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION; URINATION DISORDERS; URODYNAMICS;

EID: 34848839854     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-007-0033-5     Document Type: Short Survey

References (14)

1. Chatelain C. Denis L, Foo K, et al.: Recommendations of the international scientific committee. In 5th International Consultation on BPH. Plymouth, UK: Health Publication Ltd.; 2001:519-534.
2. American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003, 170:530-547.
3. Roehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of a dual inhibitor of 5-a-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434-441.
4. Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of alphal-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36:1-13.
5. Lepor H, Williford WO, Barry MJ, et al.: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998, 160:1358-1367.
6. Kirby RS, Roehrborn C, Boyle P, et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003, 61:119-126.
7. McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387-2398.
8. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273-2276.
9. Roehrborn CG, Abrams P, Rovner ES, et al.: Efficacy and tolerability of tolterodine extended release in men with overactive bladder and urgency urinary incontinence. BJU Int 2004, 97:1003-1006.
10. Kaplan SA, Roehrborn CG, Rovner, ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 2006, 296:2319-2328. Very important at demonstrating the safety of giving antimuscarinic agents to males with LUTS.
11. Gradini B, Realacci M, Ginepri A, et al.: Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999, 189:224-229.
12. Hopps CV, Mulhall JP. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction. J Sex Med 2007, In press.
13. Kaplan SA, Gonzalez RR, Ogiste J, et al.: Combination of an alpha-blocker, alfuzosin SR, and a PDE-5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction symptoms [abstract 1638]. J Urol 2006, 175:528. First publication with PDE-5 inhibitor in males with ED and OAB.
14. Roehrborn C, McVary K, Kaminetsky J, et al.: The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) [abstract 1636]. J Urol 2006, 175:527. Simultaneous first publication with PDE-5 inhibitor in males with ED and OAB.